Resultados del estudio aleatorizado publicado en la revista The Lancet Neurology acerca de la evaluación de la seguridad y eficacia del cenobamato en pacientes con episodios epilépticos de inicio parcial no controlados ZUG, Suiza, Nov. 18, 2019 (GLOBE NEWSWIRE) -- La empresa biofarmacéutica de reciente creación Arvelle Therapeutics GmbH, centrada en el desarrollo de tratamientos innovadores para pacientes...

Arvelle to Present at Jefferies 2019 London Healthcare Conference Arvelle to Present at Jefferies 2019 London Healthcare Conference Zug, Switzerland, November 15, 2019 - Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on...

Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published in The Lancet Neurology ZUG, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to patients with CNS disorders, today...

Arvelle Therapeutics Strengthens Management Team with Key New Hires Arvelle Therapeutics Strengthens Management Team with Key New Hires Appoints Petra Molan as Senior Vice President Commercial and                                                   Enrico Dolfini as...